Mouse VLDLR Antibody

VLDL R in Mouse Embryo. VLDL R was detected in immersion fixed frozen sections of mouse embryo using Mouse VLDL R Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2258) at 15 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counter-stained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Frozen Tissue Sections.

VLDL R in Mouse Kidney. VLDL R was detected in perfusion fixed frozen sections of mouse kidney using Goat Anti-Mouse VLDL R Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2258) at 3 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Goat IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC004). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to cell membranes of convoluted tubules. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents.

Detection of VLDLR by Western Blot The increase in CD36 levels caused by lipids in Sirt3-deficient hepatocytes is mediated by Nrf2. VLDLR mRNA abundance (a) and protein levels of VLDLR and NQO1, an Nrf-2-target gene, (b) were assessed in Huh-7 cells incubated with fatty acid free-BSA or BSA-palmitate (0.3 mM) and exposed to either vehicle or the Sirt3 inhibitor AAPBO (100 μM) for 16 h. a, p < 0.05 vs. CT. b, p < 0.05 vs. CT cells incubated with palmitate. c, p < 0.05 vs. CT cells treated with AAPBO. c, fatty acid uptake in Huh-7 cells incubated with fatty acid free-BSA or BSA-palmitate (0.3 mM) and exposed to either vehicle or the Sirt3 inhibitor AAPBO (100 μM) for 16 h was measured by the uptake of BODIPY-C16. a, p < 0.05 vs. CT. b, p < 0.05 vs. CT cells incubated with palmitate. c, p < 0.05 vs. CT cells treated with AAPBO. mRNA abundance (d) and protein levels of VLDLR (e) in Huh-7 cells transfected with control (CT) or SIRT3 siRNA and incubated in the presence or absence 0.3 mM palmitate (Pal) for 24 h. Protein levels of CD36 (f), NQO1 (g) and PPAR gamma (h) in Huh-7 cells transfected with control (CT) or SIRT3 siRNA and incubated in the presence or absence 0.3 mM palmitate (Pal) or the Nrf2 inhibitor ML385 (10 μM) for 24 h. a, p < 0.05 vs. CT siRNA cells. b, p < 0.05 vs. CT siRNA cells incubated with palmitate. c, p < 0.05 vs. SIRT3 siRNA cells. d, p < 0.05 vs. CT siRNA cells incubated with palmitate and ML385 Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/32912335), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Mouse VLDLR by Western Blot SIRT1 inhibition increases VLDLR levels and VLDL uptake in human Huh-7 cells. (A) mRNA and (B) immunoblot analysis of VLDLR in human Huh-7 cells in the absence (control, CT) or presence of 10 µM EX-527 for 24 h. Immunoblot analysis of (C) VLDLR and (D) VLDL uptake in human Huh-7 cells in the absence (control, CT) or presence of 10 µM EX-527, or in the presence of both 10 µM EX-527 and 20 µM PX-478 for 24 h. (E) Immunoblot analysis of SIRT1 and VLDLR in Huh-7 cells transfected with control siRNA or SIRT1 siRNA in the absence or presence of 20 µM PX-478. Data are presented as the mean ± SEM. Significant differences were established by Student’s t-test or one-way ANOVA with Tukey’s post-hoc test. *p < 0.05 and **p < 0.01 vs. CT. #p < 0.05, ##p < 0.01, and ###p < 0.001 vs. EX-527 or SIRT1 siRNA. n = 3 or 4 per group Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/38807218), licensed under a CC-BY license. Not internally tested by R&D Systems.